NCT00078975View on ClinicalTrials.gov

3-AP and Gemcitabine in Treating Patients With Recurrent, Unresectable, or Metastatic Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

December 31, 2005

Study Completion Date

January 7, 2009

Conditions

Pancreatic Cancer

Interventions

DRUG

gemcitabine hydrochloride

DRUG

triapine

Trial Locations (4)

L8V 5C2

Margaret and Charles Juravinski Cancer Centre, Hamilton

N6A 4L6

London Regional Cancer Program at London Health Sciences Centre, London

K1H 1C4

Ottawa Hospital Regional Cancer Centre - General Campus, Ottawa

M5G 2M9

Princess Margaret Hospital, Toronto

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

University Health Network, Toronto

OTHER

NCT00078975 - 3-AP and Gemcitabine in Treating Patients With Recurrent, Unresectable, or Metastatic Pancreatic Cancer | Biotech Hunter | Biotech Hunter